Zacks Investment Research on MSN7d
IMVT Unlikely to Pursue Batoclimab for MG & CIDP Despite Success
Immunovant IMVT announced top-line data from a late-stage study of its investigational candidate, batoclimab, for myasthenia ...
Fierce Biotech9d
Immunovant won't seek approval for autoimmune drug despite phase 3 win
Switching to IMVT-1402 extends the head starts Immunovant has already ceded to its rivals. Argenx won FDA approval for ...
Immunovant: TED Data Sets Stage For Batoclimab Regulatory Filings Going Forward
Immunovant, Inc. had positive results for batoclimab in trials for Myasthenia Gravis & CIDP; Thyroid Eye Disease data ...
BioSpace8d
Immunovant Will Drop One Myasthenia Gravis Asset, Continuing to Favor Another
Analysts were happy with batoclimab’s performance in the chronic autoimmune disorder, but Immunovant said it will continue to ...
Leerink Partners Reaffirms Their Buy Rating on Immunovant (IMVT)
Leerink Partners analyst Thomas Smith reiterated a Buy rating on Immunovant (IMVT – Research Report) yesterday and set a price target of ...
Yahoo Finance7d
Immunovant price target raised to $61 from $58 at Stifel
Stifel analyst Alex Thompson raised the firm’s price target on Immunovant (IMVT) to $61 from $58 and keeps a Buy rating on the shares following yesterday’s topline data from the Batoclimab ...
HC Wainwright Reiterates “Buy” Rating for Immunovant (NASDAQ:IMVT)
Immunovant (NASDAQ:IMVT – Get Free Report)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in ...
Yahoo Finance8d
IMVT Unlikely to Pursue Batoclimab for MG & CIDP Despite Success
Immunovant IMVT announced top-line data from a late-stage study of its investigational candidate, batoclimab, for myasthenia gravis (MG) and initial results from Period 1 of a mid-stage study of ...
Immunovant price target raised to $61 from $58 at Stifel
Stifel analyst Alex Thompson raised the firm’s price target on Immunovant (IMVT) to $61 from $58 and keeps a Buy rating on the shares following ...